[go: up one dir, main page]

UY27725A1 - Material micronizado cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento. - Google Patents

Material micronizado cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento.

Info

Publication number
UY27725A1
UY27725A1 UY27725A UY27725A UY27725A1 UY 27725 A1 UY27725 A1 UY 27725A1 UY 27725 A UY27725 A UY 27725A UY 27725 A UY27725 A UY 27725A UY 27725 A1 UY27725 A1 UY 27725A1
Authority
UY
Uruguay
Prior art keywords
preparation
procedure
medicinal product
micronized material
crystalline micronized
Prior art date
Application number
UY27725A
Other languages
English (en)
Inventor
Bender Helmut
Dr Graebner Hagen
Dr Schindler Konrad
Trunk Michael
Dr Walz Michael
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27725(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27725A1 publication Critical patent/UY27725A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hybrid Cells (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

El invento se refiere a un material micronizado cristalino de bromuro de (1a, 2B, 4B, 5a, 7B) -7-(hidróxido-2-tienil-acetil-)oxi)-9,9-dimetil-3-oxa-9-azonia-triciclo-(3.3.1.02,4)nonano, a procedimientos para su preparación así como a su utilización para la preparación de un medicamento, en particular para la preparación de un medicamento con efecto anticolinérgico.
UY27725A 2002-03-20 2003-03-18 Material micronizado cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento. UY27725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (de) 2002-03-20 2002-03-20 Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels

Publications (1)

Publication Number Publication Date
UY27725A1 true UY27725A1 (es) 2003-10-31

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27725A UY27725A1 (es) 2002-03-20 2003-03-18 Material micronizado cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento.

Country Status (36)

Country Link
EP (3) EP1487832B9 (es)
JP (1) JP4331619B2 (es)
KR (2) KR101094091B1 (es)
CN (2) CN100368410C (es)
AR (1) AR039017A1 (es)
AT (1) ATE369365T1 (es)
AU (1) AU2003212327B2 (es)
BR (1) BRPI0308513B8 (es)
CA (1) CA2479652C (es)
CO (1) CO5611105A2 (es)
CY (2) CY1106923T1 (es)
DE (2) DE10212264A1 (es)
DK (2) DK1785422T3 (es)
EA (1) EA007064B1 (es)
EC (1) ECSP045310A (es)
ES (2) ES2291619T5 (es)
HR (1) HRP20040855B1 (es)
HU (1) HUE031876T2 (es)
IL (2) IL163841A0 (es)
LT (1) LT1785422T (es)
ME (1) ME02764B (es)
MX (1) MXPA04009056A (es)
MY (1) MY139720A (es)
NO (2) NO346754B1 (es)
NZ (1) NZ535808A (es)
PE (1) PE20030838A1 (es)
PL (1) PL220730B1 (es)
PT (2) PT1785422T (es)
RS (1) RS57551B1 (es)
SA (1) SA03240098B1 (es)
SI (1) SI1487832T2 (es)
TW (1) TWI345975B (es)
UA (1) UA78295C2 (es)
UY (1) UY27725A1 (es)
WO (1) WO2003078429A1 (es)
ZA (1) ZA200405636B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US8686148B2 (en) 2003-11-03 2014-04-01 Boehringer Ingelheim International Gmbh Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
PE20050485A1 (es) 2003-11-03 2005-10-05 Boehringer Ingelheim Int Nuevas sales de tiotropio, procedimiento para su preparacion, asi como formulaciones medicamentosas que las contienen
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CA2606552A1 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
WO2006117299A2 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
MX2008001976A (es) 2005-08-15 2008-03-25 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102005059602A1 (de) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CA2627729A1 (en) 2005-12-19 2007-07-05 Sicor Inc. Novel forms of tiotropium bromide and processes for preparation thereof
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2533765A2 (en) * 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
UA115989C2 (uk) 2012-07-05 2018-01-25 Арвен Айлак Санайі Ве Тіджарет А.С. Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3191081B1 (en) 2014-09-09 2020-03-25 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
WO2017068119A1 (en) * 2015-10-23 2017-04-27 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
PT3159277T (pt) * 2015-10-23 2019-09-11 Arven Ilac Sanayi Ve Ticaret As Blister para formulação inalável de brometo de tiotrópio
CN115737610B (zh) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
BE905189A (fr) 1985-07-30 1987-01-29 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients.
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
FR2779347A1 (fr) * 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
WO2000064468A2 (en) † 1999-04-23 2000-11-02 Research Corporation Technologies Therapeutic compositions and methods for enhancing angiogenesis
EP1238661A1 (en) 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
DZ3477A1 (es) 2000-10-12 2002-04-18
EP1326862B1 (de) 2000-10-12 2004-09-15 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244842B2 (en) 2002-11-15 2007-07-17 Orchid Chemicals & Pharmaceuticals Ltd. Amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102127069A (zh) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 噻托溴铵晶体

Also Published As

Publication number Publication date
UA78295C2 (en) 2007-03-15
KR101094091B1 (ko) 2011-12-15
NO20190824A1 (no) 2004-10-14
DE50307883D1 (de) 2007-09-20
WO2003078429A1 (de) 2003-09-25
JP2005526776A (ja) 2005-09-08
EP1785422A1 (de) 2007-05-16
EA200401142A1 (ru) 2005-04-28
CN100368410C (zh) 2008-02-13
EP1487832A1 (de) 2004-12-22
DE10212264A1 (de) 2003-10-02
MY139720A (en) 2009-10-30
EP1487832B2 (de) 2018-08-29
BR0308513A (pt) 2005-01-04
PL220730B1 (pl) 2015-12-31
PT1487832E (pt) 2007-08-27
NO20044003L (no) 2004-10-14
SI1487832T1 (sl) 2007-12-31
JP4331619B2 (ja) 2009-09-16
RS57551B1 (sr) 2018-10-31
HRP20040855B1 (en) 2012-11-30
EP3053921A1 (de) 2016-08-10
ES2291619T5 (es) 2018-12-07
DK1785422T3 (en) 2017-02-27
BRPI0308513B1 (pt) 2016-04-19
CA2479652A1 (en) 2003-09-25
DK1487832T4 (en) 2018-12-10
BRPI0308513B8 (pt) 2021-05-25
DK1487832T3 (da) 2007-11-05
MXPA04009056A (es) 2005-01-25
NO344427B1 (no) 2019-12-02
IL163841A (en) 2015-10-29
KR20100135983A (ko) 2010-12-27
IL163841A0 (en) 2005-12-18
ECSP045310A (es) 2004-10-26
AR039017A1 (es) 2005-02-02
NO346754B1 (no) 2022-12-12
TWI345975B (en) 2011-08-01
HRP20040855A2 (en) 2005-06-30
TW200305421A (en) 2003-11-01
SI1487832T2 (sl) 2018-11-30
PT1785422T (pt) 2017-02-17
CN101220025A (zh) 2008-07-16
CY1118855T1 (el) 2018-01-10
MEP46708A (en) 2011-02-10
CY1106923T1 (el) 2012-09-26
HUE031876T2 (en) 2017-08-28
KR20050008662A (ko) 2005-01-21
NZ535808A (en) 2005-09-30
AU2003212327A1 (en) 2003-09-29
CA2479652C (en) 2012-07-10
ES2615460T3 (es) 2017-06-07
EP1785422B1 (de) 2016-11-16
EP1487832B9 (de) 2019-01-23
CN1642952A (zh) 2005-07-20
ES2291619T3 (es) 2008-03-01
EP1785422A8 (de) 2010-06-23
CO5611105A2 (es) 2006-02-28
ZA200405636B (en) 2006-01-25
KR101021430B1 (ko) 2011-03-15
SA03240098B1 (ar) 2008-03-24
EA007064B1 (ru) 2006-06-30
LT1785422T (lt) 2017-02-10
ATE369365T1 (de) 2007-08-15
PE20030838A1 (es) 2003-11-21
ME02764B (me) 2011-05-10
AU2003212327B2 (en) 2009-02-05
PL371799A1 (en) 2005-06-27
HK1078871A1 (zh) 2006-03-24
EP1487832B1 (de) 2007-08-08

Similar Documents

Publication Publication Date Title
UY27725A1 (es) Material micronizado cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento.
UY27342A1 (es) Agente anticolinérgico cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
UY34901A (es) ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
ECSP034571A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol
ES2127850T3 (es) Sulfonilaminopirimidinas, su obtencion y utilizacion como medicamentos.
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
UY26139A1 (es) Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos
IL183360A (en) 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
AR109263A2 (es) Composición que comprende moxidectina
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
ATE423848T1 (de) Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
ES2177671T3 (es) Benzamida enterocinetica.
UY27758A1 (es) Medicamento que contiene esteroides y un nuevo anticolinérgico
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
UY27670A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y de agentes inhibidores de la cinasa del egfr
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20160919